Press release
Glucagon-like Peptide 1 Analogues Market Size Soars Amid Obesity and Type 2 Diabetes Drug Innovation by 2033
Glucagon-like Peptide 1 Analogues Market
Key players of the GLP-1 Analogues Market include Eli Lilly and Company, Novo Nordisk A/S., Sanofi, AstraZeneca, Boehringer Ingelheim, Glenmark Pharmaceuticals, Hanmi Pharm, Amgen, Gmax Biopharm, and Sciwind Biosciences. Major innovation is happening in oral GLP 1 formulations, cardiometabolic indications, and manufacturing scale-up to expand global supply chains.
Download your exclusive sample report today: https://www.datamintelligence.com/download-sample/glucagon-like-peptide-1-analogues-market?jd
Glucagon-like Peptide 1 Analogues Market M&A & Strategic Collaborations
As per our analysis, strategic partnerships or acquisitions are gaining traction as Big Pharma seeks to fortify metabolic portfolios with GLP 1.
• Biocon plans to launch a generic version of Wegovy (semaglutide) in India and Canada by 2027, enhancing global access and challenging branded dominance.
• Eli Lilly invested USD 4.5B in a new R&D hub in Indiana (2024) to boost capacity for Mounjaro/Zepbound and new oral GLP 1s.
Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/glucagon-like-peptide-1-analogues-market?jd
Key Growth Drivers & Emerging Opportunities in the Glucagon-like Peptide 1 Analogues Market
• Explosive demand for obesity and diabetes treatments: global prescriptions grew ~38% annually between 2022-2024.
• Next-gen oral and long-acting agents (e.g., Mounjaro, Zepbound, oral semaglutide) are expanding therapeutic reach.
• Regulatory approvals and generic launches (e.g., Victoza, generic Wegovy, semaglutide) support market growth and affordability.
• AI-based patient monitoring and telehealth integration improving treatment adherence and outcomes.
• Cardiometabolic drug expansion into renal, cardiovascular, and liver disease increases lifecycle potential.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=glucagon-like-peptide-1-analogues-market?jd
Regional Market Drivers in the Glucagon-like Peptide 1 Analogues Market
North America dominates (~78% of GLP-1 receptor market), led by large sales volumes, strong reimbursement, and brand dominance.
Asia-Pacific is fast-growing, thanks to Biocon's entry and expanding obesity/diabetes burden.
Europe continues vast adoption of injectable GLP 1s with new oral formulations gaining traction.
Latin America & MEA are emerging markets, benefiting from greater healthcare initiatives and pricing strategies.
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?jd
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis for Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?jd
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glucagon-like Peptide 1 Analogues Market Size Soars Amid Obesity and Type 2 Diabetes Drug Innovation by 2033 here
News-ID: 4113907 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Voice Assistant Market to Hit US$14.20 Billion by 2032, Driven by AI and IoT Exp …
According to DataM Intelligence, the voice assistant market was valued at US$ 2.73 billion in 2024 and is projected to reach US$ 14.20 billion by 2032, growing at a CAGR of 22.89% during the forecast period (2025-2032). Growth is primarily driven by the proliferation of smart devices, expanding IoT ecosystems, and the shift toward voice-based human-machine interfaces. The hardware segment, led by smart speakers and voice-enabled devices, currently dominates the…
North America Spatial Computing Market to Hit $260.8 Billion by 2032, Driven by …
According to DataM Intelligence, the North America spatial computing market size reached US$ 58,772.07 million in 2024 and is projected to surge to US$ 260,839.20 million by 2032, representing a robust CAGR of 20.9% during the forecast period (2025-2032). Several factors are driving this strong growth. The increasing adoption of immersive technologies (AR/VR/MR) across verticals such as healthcare, manufacturing, retail, and education is unlocking new applications. Moreover, advancements in connectivity…
Pharmaceutical Drying Equipment Market to Hit $10.35 Billion by 2033 - Driven by …
According to DataM Intelligence, the pharmaceutical drying equipment market reached US$ 5.45 billion in 2023, increased to US$ 5.78 billion in 2024, and is projected to reach US$ 10.35 billion by 2033, growing at a CAGR of 6.7% during the forecast period (2025-2033). Market growth is propelled by the rapid expansion of the pharmaceutical and biopharmaceutical sectors, technological innovations in drying systems, and the rise in outsourcing of drug manufacturing…
Triple Negative Breast Cancer Market Driven by Rising Cases and Immunotherapy Ad …
According to DataM Intelligence, the Triple Negative Breast Cancer Treatment Market reached approximately US$ 0.95 billion in 2023 and is projected to reach US$ 1.66 billion by 2033, growing at a CAGR of around 6.6% during the forecast period (2025-2033). The market growth is driven by the rising global incidence of breast cancer, the aggressive nature of TNBC, and rapid advancements in immunotherapy and antibody-drug conjugates (ADCs).
Key market growth drivers…
More Releases for Analogues
GLP-1 Analogues Market Forecast: USD 471.1 Billion by 2032
The report "GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032", is projected to reach USD 471.1 billion by 2032 from USD 47.4 billion in 2024, at a CAGR of 33.2% during the forecast period
The global GLP-1 analogues market [https://www.marketsandmarkets.com/Market-Reports/glp-1-analogues-market-218746186.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] is poised for substantial growth, projected to expand from USD…
Nucleoside Analogues Market Rises Due to Antiviral Demand & Oncology Pipeline Ex …
The global Nucleoside Analogues market is expected to reach a significant multi-billion-dollar valuation by 2031, growing at a steady compound annual growth rate (CAGR) throughout the forecast period 2024-2031.
The latest Nucleoside Analogues Market Report by DataM Intelligence offers a clear analysis of global trends, market size, key players, and growth drivers. Covering emerging technologies, evolving care models, and regulatory insights, it provides strategic intelligence to help stakeholders navigate the dynamic…
Purine Analogues Drugs Market: Major Trends Reshaping the Future of the Industry
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Purine Analogues Drugs Industry Market Size Be by 2025?
Recent years have seen an explosive growth in the market size of purine analogues drugs. The market is projected to expand from $14.77 billion in 2024 to $16.34 billion in 2025, reflecting a compound annual growth rate…
GLP-1 Analogues Latest Market Analysis Report 2025
Global Info Research announces the release of the report "Global GLP-1 Analogues Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031". This report provides a detailed overview of the GLP-1 Analogues market scenario, including a thorough analysis of the GLP-1 Analogues market size, sales quantity, average price, revenue, gross margin and market share.The GLP-1 Analogues report provides an in-depth analysis of the competitive landscape, manufacturer's profiles, regional and…
GLP-1 Analogues Market Future Trends for 2025
In the rapidly evolving landscape of pharmaceuticals, the GLP-1 analogues market has emerged as a significant player in the treatment of metabolic disorders, particularly diabetes and obesity. GLP-1 analogues, or glucagon-like peptide-1 receptor agonists, mimic the action of the incretin hormone GLP-1, which plays a crucial role in regulating blood sugar levels and enhancing satiety. The market has gained tremendous traction due to increasing rates of diabetes and obesity worldwide,…
GLP-1 Analogues Market worth $471.1 billion by 2032 | MarketsandMarkets Trademar …
Browse 405 market data Tables and 59 Figures spread through 315 Pages and in-depth TOC on "GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032
The global GLP-1 analogues market [https://www.marketsandmarkets.com/Market-Reports/glp-1-analogues-market-218746186.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] is poised for substantial growth, projected to expand from USD 47.4 billion in 2024 to USD 471.1 billion by 2032,…
